Kezdőlap › Áttétes rák › Észak-Karolina › Durham
Áttétes rák klinikai vizsgálatok: Durham, NC
33 Áttétes rák vizsgálat keres résztvevőket Durham és környéke (kb. 30 mérföldes körzetben) helyszínein. Nyissa meg a vizsgálatot, hogy lássa, ki csatlakozhat, és hogyan léphet kapcsolatba a csapattal.
Hivatalos vizsgálati szöveg (angol)
Vizsgálatra keres résztvevőket? Emelje ki az oldal tetején — $99 / 30 nap →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Toborzás folyamatban1/2. fázis
- Avenzo Therapeutics Recruiting Site, Chapel Hill · 10 mérföldre
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Toborzás folyamatban2. fázis
- Duke University Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Toborzás folyamatban1/2. fázis
- Duke University, Durham
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Toborzás folyamatban2/3. fázis
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mérföldre
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Toborzás folyamatban3. fázis
- Duke Cancer Center - Investigational Chemotherapy Service, Durham
- Duke Cancer Center, Durham
- Duke University Hospital - Vascular Interventional Radiology, Durham
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Toborzás folyamatban2. fázis
- Duke Cancer Institute, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Toborzás folyamatban2/3. fázis
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · 10 mérföldre
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mérföldre
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Toborzás folyamatban3. fázis
- Duke Cancer Institute, Durham
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Toborzás folyamatban3. fázis
- University of North Carolina Medical Center, Chapel Hill · 10 mérföldre
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Toborzás folyamatban3. fázis
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · 10 mérföldre
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Toborzás folyamatban1. fázis
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill · 10 mérföldre
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Toborzás folyamatban1/2. fázis
- Duke University, Durham
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Toborzás folyamatban
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · 10 mérföldre
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Toborzás folyamatban1. fázis
- Duke Cancer Center, Durham
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Toborzás folyamatban1. fázis
- Research Site, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Toborzás folyamatban1. fázis
- Research Site, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Toborzás folyamatban1. fázis
- Duke Cancer Center, Durham
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Toborzás folyamatban1/2. fázis
- Duke University Medical Center, Durham
UNC Childhood, Adolescent, and Young Adult Cancer Cohort
Toborzás folyamatbanMegfigyeléses tanulmány
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mérföldre
UNC Metastatic Cancer Radiation Therapy Registry
Toborzás folyamatbanMegfigyeléses tanulmány
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · 10 mérföldre
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Toborzás folyamatban1/2. fázis
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mérföldre
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Toborzás folyamatban2/3. fázis
- Durham VA Medical Center, Durham, NC, Durham
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Toborzás folyamatban2/3. fázis
- Duke University Medical Center, Durham
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Toborzás folyamatban1/2. fázis
- Duke Cancer Center/ DUMC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Toborzás folyamatban1. fázis
- Duke Cancer Institute, Durham
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Toborzás folyamatban3. fázis
- Duke University, Durham
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Toborzás folyamatbanMegfigyeléses tanulmány
- Durham Veterans Administration Health Care System (DVAHCS), Durham
- Duke University Medical Center, Durham
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Toborzás folyamatban1. fázis
- Duke Cancer Center, Durham
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Toborzás folyamatban1. fázis
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mérföldre
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Toborzás folyamatban1. fázis
- Duke University Medical Center - Duke Cancer Institute, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Toborzás folyamatbanMegfigyeléses tanulmány
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mérföldre
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Toborzás folyamatban3. fázis
- Duke University - Trent Center, Durham
A Study of NX-1607 in Adults With Advanced Malignancies
Toborzás folyamatban1. fázis
- University of North Carolina, Chapel Hill · 10 mérföldre
Áttétes rák vizsgálatok más városokban
- Houston, TX104 tanulmány
- New York City, NY93 tanulmány
- Nashville, TN70 tanulmány
- Boston, MA63 tanulmány
- Los Angeles, CA57 tanulmány
- St. Louis, MO54 tanulmány
- Arlington, VA53 tanulmány
- Philadelphia, PA46 tanulmány
- Chicago, IL45 tanulmány
- San Antonio, TX44 tanulmány
- Washington, DC43 tanulmány
- Dallas, TX42 tanulmány
Egyéb vizsgálatok: Durham
- Mellrák64 tanulmány
- Rák (minden típus)58 tanulmány
- Nem kis sejtes tüdőrák39 tanulmány
- Multiplex mielóma37 tanulmány
- Akut mieloid leukémia33 tanulmány
- Prosztatarák32 tanulmány
- Tüdőrák32 tanulmány
- Kolorektális rák28 tanulmány
- Petefészekrák27 tanulmány
- Krónikus limfocitás leukémia27 tanulmány
- Szívelégtelenség26 tanulmány
- Hasnyálmirigyrák24 tanulmány
Forrás: ClinicalTrials.gov, adatok lekérve: 2026. okt. 6.. Minden vizsgálat saját alkalmassági feltételeket határoz meg; a döntést a vizsgálati csapat hozza meg.